| Stage of cancer; no. (%) of patients* | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All stages n = 2927 | Stage 0 n = 424 | Stage I n = 1118 | Stage II n = 938 | Stage III n = 233 | Stage IV n = 123 | Unknown n = 91 | |||||||||||||
| % of all patients | 100 | 14 | 38 | 32 | 8 | 4 | 3 | ||||||||||||
| Sex, female | 2909 | (99) | 422 | (>99) | 1116 | (>99) | 933 | (99) | 229 | (98) | 122 | (99) | 87 | (96) | |||||
| Age at diagnosis | |||||||||||||||||||
| Median (range) | 61 | (27–102) | 58 | (28–94) | 62 | (29–98) | 58 | (27–101) | 59 | (30–95) | 64 | (35–96) | 74 | (39–102) | |||||
| < 40 | 127 | (4) | 6 | (1) | 38 | (3) | 62 | (7) | 15 | (6) | 5 | (4) | 1 | (1) | |||||
| 40–49 | 538 | (18) | 100 | (24) | 176 | (16) | 201 | (21) | 46 | (20) | 9 | (7) | 6 | (7) | |||||
| 50–59 | 719 | (25) | 124 | (29) | 261 | (23) | 226 | (24) | 62 | (27) | 33 | (27) | 13 | (14) | |||||
| 60–69 | 660 | (23) | 95 | (22) | 290 | (26) | 185 | (20) | 40 | (17) | 29 | (24) | 21 | (23) | |||||
| 70–79 | 583 | (20) | 74 | (17) | 267 | (24) | 164 | (17) | 35 | (15) | 23 | (19) | 20 | (22) | |||||
| ≥ 80 | 300 | (10) | 25 | (6) | 86 | (8) | 100 | (11) | 35 | (15) | 24 | (20) | 30 | (33) | |||||
| Margin status | |||||||||||||||||||
| Positive | 123 | (4) | 14 | (3) | 20 | (2) | 39 | (4) | 26 | (11) | 15 | (12) | 9 | (10) | |||||
| Negative | 2356 | (80) | 371 | (88) | 990 | (89) | 795 | (85) | 168 | (72) | 32 | (26) | 0 | (0) | |||||
| Close | 165 | (6) | 29 | (7) | 56 | (5) | 61 | (7) | 16 | (7) | 3 | (2) | 0 | (0) | |||||
| Unknown | 283 | (10) | 10 | (2) | 52 | (5) | 43 | (5) | 23 | (10) | 73 | (59) | 82 | (90) | |||||
| Size of tumour, cm | |||||||||||||||||||
| Median (range) | 1.7 | (0.1–9.9) | 1.5 | (0.1–9.9) | 1.2 | (0.1–2.0) | 2.5 | (0.1–9.9) | 5.4 | (0.1–9.9) | 4.3 | (0.4–9.9) | 1.3 | (1.1–1.5) | |||||
| < 1.0 | 529 | (18) | 122 | (29) | 370 | (33) | 27 | (3) | 8 | (3) | 2 | (2) | 0 | (0) | |||||
| 1.0–2.0 | 1110 | (38) | 139 | (33) | 708 | (63) | 227 | (24) | 20 | (9) | 14 | (11) | 2 | (2) | |||||
| 2.1–5.0 | 822 | (28) | 90 | (21) | 0 | (0) | 628 | (67) | 70 | (30) | 34 | (28) | 0 | (0) | |||||
| > 5.0 | 204 | (7) | 34 | (8) | 0 | (0) | 19 | (2) | 115 | (49) | 36 | (29) | 0 | (0) | |||||
| Unknown | 262 | (9) | 39 | (9) | 40 | (4) | 37 | (4) | 20 | (9) | 37 | (30) | 89 | (98) | |||||
| ER status | |||||||||||||||||||
| Positive | 1920 | (66) | 30 | (7) | 943 | (84) | 707 | (75) | 165 | (71) | 63 | (51) | 12 | (13) | |||||
| Negative | 457 | (16) | 13 | (3) | 139 | (12) | 219 | (23) | 57 | (24) | 26 | (21) | 3 | (3) | |||||
| Unknown | 550 | (19) | 381 | (90) | 36 | (3) | 12 | (1) | 11 | (5) | 34 | (28) | 76 | (84) | |||||
| Grade | |||||||||||||||||||
| 1 | 784 | (27) | 85 | (20) | 487 | (44) | 177 | (19) | 22 | (9) | 9 | (7) | 4 | (4) | |||||
| 2 | 1050 | (36) | 152 | (36) | 413 | (37) | 361 | (38) | 82 | (35) | 35 | (28) | 7 | (8) | |||||
| 3 | 875 | (30) | 147 | (35) | 195 | (17) | 383 | (41) | 108 | (46) | 38 | (31) | 4 | (4) | |||||
| Unknown | 218 | (7) | 40 | (9) | 23 | (2) | 17 | (2) | 21 | (9) | 41 | (33) | 76 | (84) | |||||
| LVI | |||||||||||||||||||
| Positive | 519 | (18) | 0 | (0) | 77 | (7) | 297 | (32) | 114 | (49) | 28 | (23) | 3 | (3) | |||||
| Negative | 1747 | (60) | 18 | (4) | 994 | (89) | 600 | (64) | 85 | (36) | 40 | (33) | 10 | (11) | |||||
| Unknown | 661 | (23) | 406 | (96) | 47 | (4) | 41 | (4) | 34 | (15) | 55 | (45) | 78 | (86) | |||||
| No. of positive nodes | |||||||||||||||||||
| 0 | 1439 | (49) | 71 | (17) | 1005 | (90) | 339 | (36) | 17 | (7) | 7 | (6) | 0 | (0) | |||||
| 1–3 | 497 | (17) | 0 | (0) | 0 | (0) | 422 | (45) | 65 | (28) | 10 | (8) | 0 | (0) | |||||
| ≥ 4 | 252 | (9) | 0 | (0) | 0 | (0) | 124 | (13) | 107 | (46) | 20 | (16) | 1 | (1) | |||||
| Positive, no. unknown | 3 | (<1) | 0 | (0) | 0 | (0) | 0 | (0) | 3 | (1) | 0 | (0) | 0 | (0) | |||||
| Nodal status unknown | 736 | (25) | 353 | (83) | 113 | (10) | 53 | (6) | 41 | (18) | 86 | (70) | 90 | (99) | |||||
| SMPBC attender | |||||||||||||||||||
| Yes | 1574 | (54) | 302 | (71) | 704 | (63) | 431 | (46) | 81 | (35) | 33 | (27) | 23 | (25) | |||||
| No | 1353 | (46) | 122 | (29) | 414 | (37) | 507 | (54) | 152 | (65) | 90 | (73) | 68 | (75) | |||||
| Screen detected† | |||||||||||||||||||
| Yes | 971 | (62) | 238 | (79) | 499 | (71) | 189 | (44) | 25 | (31) | 11 | (33) | 9 | (39) | |||||
| No | 603 | (38) | 64 | (21) | 205 | (29) | 242 | (56) | 56 | (69) | 22 | (67) | 14 | (61) | |||||
Note: ER = estrogen receptor, LVI = lymphovascular invasion, SMPBC = Screening Mammography Program of British Columbia. *Unless otherwise indicated. †Defined as diagnosis of breast cancer within 1 year after abnormal results on screening. For patients with synchronous bilateral disease, the first diagnosis was used to define the screen-detection variable, which was then assigned to both diagnoses.